News
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
Jaguar Health, Inc. announces extended grace period from Nasdaq for bid price compliance. Top line results awaited for crofelemer's cancer therapy-related diarrhea prevention trial -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
Dr. Massimo Radaelli appointed as President of Jaguar International to expand commercial footprint globally with recent out-license agreement. Key pharmaceutical industry leader with vast experience and expertise -
-
-
-
-